J
Johnson & Johnson
JNJ · Healthcare
Q4 FY2025
Earning ended Dec 28, 2025Report generated Mar 10, 2026
The Market Is Still Pricing In Yesterday's J&J
Wall Street is so focused on Stelara's biosimilar erosion that it's missing the more important story: J&J has quietly assembled one of the most formidable oncology biologics platforms on the planet while simultaneously building procedure-locking positions in pulsed-field ablation and cardiovascular intervention — two markets still in the early innings of adoption curve where the dominant platform takes all the economics.
Flowly Score
Apr 15 Close
+59%$238.67
Fair Value
$380.00
71
Strongat $238.67
Business Strength8/10
A patent fortress with genuine process power — the organizational machinery that keeps building tomorrow's blockbusters is the real moat, not just today's patent estate. The governance blemish from the talc liability maneuvers is real and prevents a 9, but the underlying commercial engine is elite.
Financial Resilience7/10
Five years of relentlessly consistent free cash flow across litigation chaos, a major corporate separation, and macro turbulence is about the strongest proof of business quality you can find. The rising debt load and declining cash position from recent acquisitions warrant watching, but the cash generation capacity makes this a manageable burden.
Growth & Trajectory7/10
The Darzalex-Tremfya-Spravato growth quartet is not patching the Stelara hole — it is building a structurally different and more valuable pharmaceutical franchise, and the cardiovascular MedTech pivot is quietly compounding procedure-locking positions in high-stakes clinical settings. The orthopedics separation in 2027 will accelerate the portfolio's center of gravity shift toward growth.
Valuation7/10at $242.59
The market is applying a discount that reflects the Stelara transition and a lingering conglomerate overhang from an era that ended with the Kenvue spin — the post-separation entity is meaningfully higher quality than the multiple suggests. Across every scenario in the DCF, this business is underpriced for what it actually generates.
Risk5/10
The talc litigation is genuinely unresolved — courts have repeatedly rejected the preferred resolution structure, and a multi-district trial outcome remains a fat-tail event that no DCF captures cleanly. Layered on top: antibody-drug conjugates are actively rewriting standard-of-care in J&J's core oncology franchises, IRA pricing negotiation is permanently shrinking blockbuster economics, and Stelara erosion is still mid-cycle.
The investment case here is a quality business going through a visible, narrative-driven discount. Stelara erosion is real but finite; what's replacing it — Darzalex colonizing earlier treatment lines, Tremfya on a trajectory toward blockbuster status, Spravato opening a new category in treatment-resistant depression — is structurally more durable and commands higher pricing power than the immunology franchise it's succeeding. The current multiple prices in a company still dragging the weight of consumer healthcare; what actually trades today is a focused pharmaceutical and medtech engine with 17% returns on invested capital and management explicitly targeting double-digit revenue growth by decade's end. The company is in the middle of a deliberate transformation from stolid healthcare conglomerate to science-intensive growth platform, and the MedTech repositioning is underappreciated. The Shockwave acquisition and the Varipulse pulsed-field ablation platform aren't incremental — they're bets on two procedure categories where hospital EP programs and cath labs standardize around a single vendor the way airlines standardize around an avionics suite. When that standardization happens, the switching costs become visceral and years-long. Add the Optava robotic surgery platform pursuing a de novo FDA pathway specifically to distinguish itself from commoditizing incumbents, and MedTech's quality trajectory is quietly improving. The single biggest risk is talc, specifically named: not the liability amount itself, but the unpredictability of multi-district litigation when a company's preferred resolution structure has been rejected by federal courts multiple times. The worst-case scenario isn't existential for a business generating this much cash — but an adverse ruling requiring material cash settlement precisely during the Stelara replacement cycle could force capital allocation tradeoffs that would genuinely damage the pipeline reinvestment rate, the one input that determines whether this transformation succeeds.